Laboratory Corporation of America Holdings (LSE:0JSY) - Stock Price, News & Analysis

0JSY Stock Overview

0JSY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	2/6

Rewards

Trading at 65.4% below our estimate of its fair value

Earnings are forecast to grow 21.03% per year

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Profit margins (3.2%) are lower than last year (7.2%)

Significant insider selling over the past 3 months

Laboratory Corporation of America Holdings Competitors

Integrated Diagnostics Holdings

LSE:IDHC

US$183.0m

Smith & Nephew

LSE:SN.

UK£8.6b

Mediclinic International

LSE:MDC

UK£3.7b

ConvaTec Group

LSE:CTEC

UK£5.2b

Price History & Performance

Summary of all time highs, changes and price drops for Laboratory Corporation of America Holdings
Historical stock prices
Current Share Price	US$205.73
52 Week High	US$242.36
52 Week Low	US$195.90
Beta	0.99
1 Month Change	-5.54%
3 Month Change	-9.38%
1 Year Change	-8.97%
3 Year Change	-23.69%
5 Year Change	24.21%
Change since IPO	16.62%

Recent updates

Shareholder Returns

	0JSY	GB Healthcare	GB Market
7D	1.1%	-0.1%	1.7%
1Y	-9.0%	-29.7%	1.4%

Return vs Industry: 0JSY exceeded the UK Healthcare industry which returned -29.7% over the past year.

Return vs Market: 0JSY underperformed the UK Market which returned 1.1% over the past year.

Price Volatility

Is 0JSY's price volatile compared to industry and market?
0JSY volatility
0JSY Average Weekly Movement	2.9%
Healthcare Industry Average Movement	7.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0JSY has not had significant price volatility in the past 3 months.

Volatility Over Time: 0JSY's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	67,000	Adam Schechter	www.labcorp.com

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Laboratory Corporation of America Holdings Fundamentals Summary

How do Laboratory Corporation of America Holdings's earnings and revenue compare to its market cap?
0JSY fundamental statistics
Market cap	US$16.73b
Earnings (TTM)	US$399.20m
Revenue (TTM)	US$12.30b

43.1x

P/E Ratio

1.4x

P/S Ratio

Is 0JSY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JSY income statement (TTM)
Revenue	US$12.30b
Cost of Revenue	US$8.89b
Gross Profit	US$3.41b
Other Expenses	US$3.01b
Earnings	US$399.20m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	4.74
Gross Margin	27.74%
Net Profit Margin	3.25%
Debt/Equity Ratio	63.8%

How did 0JSY perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

62%

Payout Ratio

Does 0JSY pay a reliable dividends?

See 0JSY dividend history and benchmarks

When do you need to buy 0JSY by to receive an upcoming dividend?
Laboratory Corporation of America Holdings dividend dates
Ex Dividend Date	May 24 2024
Dividend Pay Date	Jun 12 2024
Days until Ex dividend	24 days
Days until Dividend pay date	43 days

Does 0JSY pay a reliable dividends?

See 0JSY dividend history and benchmarks

0JSY Stock Overview

Rewards

Risk Analysis

Laboratory Corporation of America Holdings Competitors

LSE:IDHC

US$183.0m

LSE:SN.

UK£8.6b

LSE:MDC

UK£3.7b

LSE:CTEC

UK£5.2b

Price History & Performance

Recent News & Updates

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.35 in 1Q 2023)

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Recent updates

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.35 in 1Q 2023)

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

CFO & Executive VP recently sold US$4.4m worth of stock

Upcoming dividend of US$0.72 per share

Full year 2023 earnings released: EPS: US$4.35 (vs US$14.04 in FY 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.91 in 3Q 2022)

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold US$1.1m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

First quarter 2023 earnings released: EPS: US$2.41 (vs US$5.28 in 1Q 2022)

Insider recently sold US$1.3m worth of stock

Full year 2022 earnings released: EPS: US$14.04 (vs US$24.58 in FY 2021)

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Now 21% undervalued

Upcoming dividend of US$0.72 per share at 1.2% yield

Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023

Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023

Labcorp Announces Executive Changes

Upcoming dividend of US$0.72 per share

Third quarter 2022 earnings released: EPS: US$3.91 (vs US$6.10 in 3Q 2021)

Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors

Labcorp Declares Quarterly Dividend, Payable on December 9, 2022

Laboratory Corporation of America Holdings (NYSE:LH) acquired Certain Outreach Laboratory Assets from Certain Outreach Laboratory Assets.

Laboratory Corporation of America Holdings to Report Q3, 2022 Results on Oct 27, 2022

Laboratory Corporation of America Holdings (NYSE:LH) acquired Clinical Outreach Laboratory Business and Select Related Assets of RWJBarnabas Health.

Upcoming dividend of US$0.72 per share

Senior VP & Chief Accounting Officer recently sold US$467k worth of stock